EMvision Medical Devices Ltd. EMV
ASX · Australia · Health Technology
AUD 1.57-0.02 (-1.26%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
MakklerAI · PRO
MakklerPRO is required for MakklerAI questions and forward scenarios grounded in structured data for the selected stock.
Upgrade to MakklerPROUpgrade to MakklerPRO to see the Makkler Fair Value calculation, the fundamental score and the multiples behind it.
Upgrade to MakklerPROUpgrade to MakklerPRO to see a 1-5 score for profitability, growth, cash-flow quality, and balance-sheet health.
Upgrade to MakklerPROUpgrade to MakklerPRO to see an AI-generated executive summary and bull/bear breakdown built from this stock's financial data.
Upgrade to MakklerPRO| Company | Market cap | P/E | P/B | P/S | Net margin | Revenue growth | Dividend yield | Beta |
|---|---|---|---|---|---|---|---|---|
| EMVEMvision Medical Devices Ltd. | AUD 147.80M | — | 9.3 | — | — | — | 0.0% | 1.4 |
| OILOptiscan Imaging Limited | AUD 141.16M | — | 8.8 | 314 | -1,556.7% | -52.9% | 0.0% | 0.6 |
| ARXAroa Biosurgery Ltd | AUD 181.60M | 45.0 | 2.0 | 2.1 | 4.3% | 19.2% | 0.0% | 1.6 |
| OCCOrthocell Ltd | AUD 208.38M | — | 6.1 | 18.3 | -122.0% | 51.1% | 0.0% | 0.3 |
| LDXLumos Diagnostics Holdings Ltd. | AUD 97.17M | — | 2.9 | 4.9 | -38.9% | 1.4% | 0.0% | 1.9 |
| VFYVitrafy Life Sciences Ltd. | AUD 304.96M | — | 7.1 | 1,530 | -9,584.2% | 159.1% | 0.0% | 1.8 |
| TTXTetratherix Limited | AUD 334.27M | — | 10.3 | 364 | -1,015.1% | — | 0.0% | 2.1 |
| SOMSomnomed Limited | AUD 64.83M | — | 1.5 | 0.6 | -2.3% | 2.7% | 0.0% | 1.5 |
| CYCCyclopharm Limited | AUD 57.21M | — | 1.8 | 1.6 | -53.2% | 12.1% | 0.0% | 1.5 |
| Peer median | 45.0 | 4.5 | 11.6 | -87.6% | 12.1% | 0.0% | 1.5 |
Peers are selected automatically from companies in the same industry. Extreme ratios (a loss-making company's P/E, or one distorted by a one-off item) are not adjusted away, which is why the summary row uses the median rather than the average. Not investment advice. The ratios in this table come from one outside provider for every company, so the comparison is internally consistent; they can differ from the filing-derived ratios higher up the page because the definitions differ.